<DOC>
	<DOCNO>NCT02619435</DOCNO>
	<brief_summary>The purpose study purpose study ass regorafenib active enough , term 6-month progression-free rate , warrant comparative study patient RAS-mutant advanced colorectal cancer progress first-line oxaliplatin-based chemotherapy plus bevacizumab .</brief_summary>
	<brief_title>Regorafenib Monotherapy Second-line Treatment Patients With RAS-mutant Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>1 . Histologically confirm diagnosis colorectal adenocarcinoma 2 . Any RAS mutation prevent treatment antiEGFR antibody 3 . Stage IV 4 . Measurable disease accord RECIST v. 1.1 5 . Disease progression follow treatment fluoropyrimidine , oxaliplatin bevacizumab , treatment irinotecan consider immediately mandatory Investigator 6 . Age ≥ 18 year 7 . ECOG Performance Status 01 8 . Neutrophils &gt; 1500 / mm3 , platelet &gt; 100,000 / mm3 , hemoglobin &gt; 9 g/dL without transfusion granulocytecolony stimulate factor ( GCSF ) hematopoietic growth factor . 9 . Bilirubin level &lt; 1.5 x ULN 10 . Glomerular filtration rate &gt; 30 mL/min/1.73 m2 accord Modified Diet Renal Disease abbreviate formula 11 . AST ( SGOT ) ALT ( SGPT ) ≤ 3.0 x ULN ( ≤ 5 x ULN liver metastasis present ) 12 . Alkaline phosphatase ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) 13 . Serum creatinine &lt; 1.5 x ULN 14 . Amylase lipase ≤ 1.5 x ULN 15 . INR aPTT ≤ 1.5 x ULN . Subjects therapeutically treat agent warfarin heparin allow participate underlying abnormality coagulation parameter exist per medical history . 16 . Understand , willing give consent , sign write informed consent form ( ICF ) prior undergo studyspecific procedure . 17 . If female childbearing potential , negative result pregnancy test perform maximum 7 day initiation study treatment . 18 . If potentially childbearing female , male , agree use adequate contraception ( eg , abstinence , intrauterine device , oral contraceptive , doublebarrier method ) date ICF sign 8 week last dose study drug . 19 . Life expectancy great 3 month 1 . Previous treatment regorafenib irinotecan 2 . Are take strong cytochrome P ( CYP ) CYP3A4 inhibitor ( eg , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telithromycin , voriconazole ) strong CYP3A4 inducer ( eg , carbamazepine , phenobarbital , phenytoin , rifampin , St. John 's Wort ) 3 . Have major surgical procedure , open biopsy , significant traumatic injury within 28 day prior initiation study treatment 4 . Have congestive heart failure classify New York Heart Association Class 2 high 5 . Have unstable angina ( angina symptom rest ) newonset angina &lt; 3 month prior screen . 6 . Have myocardial infarction &lt; 6 month prior initiation study treatment . 7 . Have cardiac arrhythmia require antiarrhythmic therapy , exception beta blocker digoxin . 8 . Have arterial venous thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis , pulmonary embolism within 6 month prior initiation study treatment 9 . Symptomatic brain metastasis meningeal tumor 10 . Patients evidence history bleed diathesis 11 . Uncontrolled hypertension ( systolic blood pressure [ SBP ] &gt; 140 mmHg diastolic blood pressure [ DBP ] &gt; 90 mmHg ) 12 . Have interstitial lung disease ongoing sign symptoms time informed consent obtain 13 . Have persistent proteinuria &gt; 3.5 g/24 hour measure urine protein creatinine ratio random urine sample ( &lt; Grade 3 , CTCAE v 4.0 ) . 14 . Have unresolved toxicity higher National Cancer InstituteCommon Terminology Adverse Events version 4.0 ( CTCAE v 4.0 ) Grade 1 attributed prior therapy/procedure , exclude alopecia and/or oxaliplatininduced neurotoxicity ≤ Grade 2 hemoglobin ≥ 9 g/dL per inclusion criterion 15 . Patients take oral medication , require intravenous alimentation , prior surgical procedure affect absorption , active peptic ulcer disease 16 . Pregnant lactate woman 17 . Any malignancy within 5 year ( except adequately treat carcinoma situ cervix non melanoma skin cancer ) 18 . Any unstable systemic disease ( include active infection , significant hepatic , renal metabolic disease ) , metabolic dysfunction , physical examination finding , clinical laboratory find contraindicates use regorafenib render patient high risk treatment complication 19 . Sexually active male female ( childbearing potential ) unwilling practice contraception study . 20 . Have serious unstable illness , medical , psychological , social condition , could jeopardize safety subject and/or his/her compliance study procedure , may interfere subject 's participation study evaluation study result . 21 . Have know hypersensitivity study drug , study drug class , excipients formulation study drug . 22 . Have close affiliation investigational site ( eg , close relative investigator ) dependent person ( eg , employee student work investigational site ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RAS-mutant</keyword>
</DOC>